OFIRNOFLAST Shows Promise in Lower‑risk MDS
MDS Oral - Clinical - OFIRNOFLAST NEK7i in LR MDS - Bafna #EHA2026 #MDSsm #leusm Conclusions https://t.co/2WYNjZs2Js
Ofirnoflast NEK7 Inhibitor Shows Promise in Lower‑risk MDS
MDS Oral - Clinical - OFIRNOFLAST NEK7i in LR MDS - Bafna #EHA2026 #MDSsm #leusm https://t.co/6b7pX0rR8g
Precision Hematology Drives Next‑Gen Clinical Trial Design
Precision hematology: Next generation clinical trial design - #EHA2026 #ClinicalTrials #ctsm Simon Richardson #ALLsm https://t.co/zoIuCqaMpG
WGS Uncovers Missed Clinically Relevant MDS Biomarkers
Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 https://t.co/Je6wyHzypT #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI
Zoledronic Acid Prevents Bone Loss in Lymphoma Therapy
Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial [Dec 29, 2012] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth #NCT00352846
PurIST Classifier Validated for Therapy Selection in Pancreatic Cancer
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine
WGS Uncovers Clinically Relevant Findings Missed in MDS
Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS] - @AlexBataller et al @garciamanero @UTMDAnderson @TempusAI #ASCO26 abst 6570 Pst 363 https://t.co/t7aNW89eRL #MDSsm #leusm #cagenome
New Multi-Center Registry Uncovers Hematologic Cancer Biomarkers
AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for Pts w/ hematologic malignancies - @mtmdphd et al. @TempusAI & IFLI - Instit Follicular Lymphoma Innovation #ASCO26 abstr TPS7105, Poster 599a https://t.co/70G0v1P968 #NCT07154823 #lymsm #cagenome https://t.co/WTLsn97BCx
Two Decades of Evolving ASCO Clinical Trial Trends
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025) - Overheu #ASCO26 Abstract # 11024, Poster Bd # 7 https://t.co/JYI0LY7FbU #ClinicalTrials #ctsm @ASCO
Ivonescimab Shows
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc
Phase 3 Trial
#ASCO26 LBA2 - Dickson -SARC041: Ph3 DBRCT abemaciclib vs placebo in Pts w/ adv dedifferentiated liposarcoma [May 31, 2026] https://t.co/oWEeVo2oyq #NCT04967521 #scmsm
Perioperative Ap
#ASCO26 LBA1 - Taplin - Perioperative APA + ADT - prostate CA [May 31, 2026] https://t.co/oWEeVo2oyq #NCT03767244 #pcsm
AQUARIUS Registry Unveils Multi‑Center Biomarker Discovery for Blood Cancers
AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for Pts w/ hematologic malignancies - @mtmdphd et al. @TempusAI & IFLI - Instit Follicular Lymphoma Innovation #ASCO26 abstr TPS7105, Poster 599a https://t.co/70G0v1P968 #NCT07154823 #lymsm #cagenome
Len
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/Gx8qHe4PLo
Genomics Predict Venetoclax Response in T(
Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax [Dec 7, 2024] @MKaddouraMD et al. @lbaughn #ASH24 Abst 249 https://t.co/TLon5bCQ3i #mmsm #PrecisionMedicine